Alumis News and Activities
Presence
Alumis is a biotechnology company that develops precision medicines for immune-mediated diseases. Its main products and services include clinical-stage drug candidates and research programs for patients, healthcare providers, and biopharma partners.
Alumis products and services overview:
- Autoimmune therapies
- Precision medicines
- Drug discovery
- Clinical development
- Research services
Revenue: ~$0 million
Employees: 180
Headquarters: South San Francisco, United States (USA)
Alumis is one of the...
Alumis is a company listed under the stock ticker ALMS (US).
Executives
View the org chart displaying its 36 main executives
Most searched biographies at Alumis
- Martin Babler, Chief Executive Officer and Chairman
- Sapna Srivastava, Director
- Zhengbin Yao, Director
Create your alert
to follow the executive moves at Alumis.
Biotechnology
Alumis has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
- NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
- Rallybio and Avenzo Therapeutics have announced they will merge (posted on June 1 2026)..
Popular contacts in Biotechnology
News
Press releases by Alumis
- Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005 | Alumis Inc.
- Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements | Alumis Inc.
- Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024 | Alumis Inc.
- Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference | Alumis Inc.
- Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study | Alumis Inc.
- Alumis to Participate in Upcoming September Investor Conferences | Alumis Inc.
- Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements | Alumis Inc.
- Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis | Alumis Inc.
- News Releases | Alumis Inc.
- Presentations | Alumis Inc.
- View more press releases Close
Social media about Alumis
- Alumis on Wikipedia, Google News & Yahoo Finance
- Alumis on LinkedIn, X (Twitter) & YouTube
